Feb 1, 2025, 13:44
CLL12 study supports using the watch-and-wait approach for early-stage CLL
Jonathan Friedberg, Director of Wilmot Cancer Institute, shared a recent article by Petra Langerbeins, et al. on X:
CLL12 study supports using the watch-and-wait approach as the standard of care for early-stage CLL, including high-risk patients.
Ongoing SWOG Cancer Research Network S1925 trial evaluates early venetoclax-based treatment for high risk patients.
Authors: Petra Langerbeins, et al.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 1, 2025, 13:00
Feb 1, 2025, 12:49
Feb 1, 2025, 12:21
Feb 1, 2025, 09:08
Feb 1, 2025, 09:02